<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0d2aa8b3-2d00-f50a-c4cc-92748288e6aa"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information
needed  to use KINEVAC safely and effectively. See full prescribing
information for KINEVAC<br/>KINEVAC (sincalide for injection),
for intravenous use Initial U.S. Approval:  1976</title>
   <effectiveTime value="20231018"/>
   <setId root="1408aabb-6982-48e5-ae9f-504ec43b0003"/>
   <versionNumber value="13"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="849234661" root="1.3.6.1.4.1.519.1"/>
            <name>Bracco Diagnostics Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="849234661" root="1.3.6.1.4.1.519.1"/>
                  <name>Bracco Diagnostics Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="069263643" root="1.3.6.1.4.1.519.1"/>
                        <name>Jubilant HollisterStier LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-0556" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-0556" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="840771732" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi  USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-0556" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-0556" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="482220311" root="1.3.6.1.4.1.519.1"/>
                        <name>Bachem AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-0556" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9325f412-632b-4b7f-b470-4ff5c53e3383"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20180122"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0270-0556" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>KINEVAC</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sincalide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5" unit="ug"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M03GIQ7Z6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sincalide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="M03GIQ7Z6P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Sincalide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="170" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="30" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F7LTH1E20Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>arginine hydrochloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="15" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JNJ23Q2COM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lysine hydrochloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="9" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CI71S98N1Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>potassium phosphate, dibasic</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="4" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>methionine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.04" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4VON5FNS3C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium metabisulfite</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.005" unit="ug"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-0556-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19760721"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA017697" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19760721"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_01">
               <id root="032930c7-4e2b-8fd6-2e99-5f56b86ad063"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <effectiveTime value="20231018"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table ID="t7726121793" width="100%">
                           <colgroup>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td>Contraindications (<linkHtml href="#Section_4">4</linkHtml>)</td>
                                 <td align="right">10/2023</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)</td>
                                 <td align="right">10/2023</td>
                              </tr>
                              <tr>
                                 <td>       Anaphylaxis, Anaphylactic Shock and Other Serious Hypersensitivity
Reactions (<linkHtml href="#Section_5.1">5.1</linkHtml>) </td>
                                 <td align="right">10/2023</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p471301690664351"/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="c5f6fe6a-841d-4768-895d-880df9c67334"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="p284511301546455495">Kinevac is indicated in adults to:</paragraph>
                  <list listType="unordered" ID="l28521301546455505" styleCode="Disc">
                     <item>to stimulate gallbladder contraction, as may be assessed
by various methods of diagnostic imaging, or to obtain by duodenal
aspiration a sample of concentrated bile for analysis of cholesterol,
bile salts, phospholipids, and crystals; </item>
                     <item>to stimulate pancreatic secretion in combination with secretin
prior to obtaining a duodenal aspirate for analysis of enzyme activity,
composition, and cytology; </item>
                     <item>to accelerate the transit of a barium meal through the small
bowel, thereby decreasing the time and extent of radiation associated
with fluoroscopy and x-ray examination of the intestinal tract.</item>
                  </list>
               </text>
               <effectiveTime value="20181201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p5664316161546528010">Kinevac is a cholecystokinin (CCK) analog indicated in adults to:</paragraph>
                        <list listType="unordered" ID="l5669116161546528074" styleCode="Disc">
                           <item>stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. (<linkHtml href="#Section_1">1</linkHtml>)</item>
                           <item>stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. (<linkHtml href="#Section_1">1</linkHtml>)</item>
                           <item>accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. (<linkHtml href="#Section_1">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="2f81d2b6-fab9-bc7f-3dd0-763222f6d8e0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p5675316161546529715">Recommended Adult Dosage and
Administration by Indication:<br/>
                           <content styleCode="underline">To Stimulate Contraction
of the Gallbladder</content>
                        </paragraph>
                        <list listType="unordered" ID="l6152716161546529747" styleCode="Disc">
                           <item>0.02 mcg/kg as a single dose over 30 to 60 seconds via intravenous
injection. If satisfactory contraction does not occur in 15 minutes,
administer a dose of 0.04 mcg/kg over 30 to 60 seconds. (<linkHtml href="#Section_2.1">2.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Alternatively consider an intravenous infusion to
reduce gastrointestinal adverse reactions</content>:  0.12 mcg/kg diluted
in 100 mL of 0.9% Sodium Chloride Injection USP and infused over 50
minutes at a rate of 2 mL per minute. (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_5.3">5.3</linkHtml>)</item>
                        </list>
                        <paragraph ID="p6157916161546529858">
                           <content styleCode="underline">To Stimulate Pancreatic
Secretion in Combination with Secretin</content>
                        </paragraph>
                        <list listType="unordered" ID="l6402316161546529897" styleCode="Disc">
                           <item>30 minutes after initiation of secretin for injection, administer
0.02 mcg/kg diluted in 30 mL of 0.9% Sodium Chloride Injection USP
and infused over 30 minutes at a rate of 1 mL per minute. (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_2.2">2.2</linkHtml>)</item>
                        </list>
                        <paragraph ID="p3347716161546529918">
                           <content styleCode="underline">To Accelerate Transit
of a Barium Meal Through the Small Intestine</content>
                        </paragraph>
                        <list listType="unordered" ID="l6425116161546529965" styleCode="Disc">
                           <item>After the barium meal is beyond the proximal jejunum, administer
0.04 mcg/kg over 30 to 60 seconds via intravenous injection. (<linkHtml href="#Section_2.1">2.1</linkHtml>)</item>
                           <item>If satisfactory transit of the barium meal has not occurred
in 30 minutes, administer a second dose of 0.04 mcg/kg over 30 to
60 seconds. (<linkHtml href="#Section_2.1">2.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Alternatively consider an intravenous infusion to
reduce gastrointestinal adverse reactions</content>:  0.12 mcg/kg diluted
in 100 mL 0.9% Sodium Chloride Injection USP and infused over 30 minutes.
(<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_5.3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="dfe82387-4fa0-5742-559e-e7751f7143c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage
and Administration Instructions</title>
                     <text>
                        <paragraph ID="p31124301546455778">The recommended dosage and administration
of Kinevac by indication is shown in Table 1. For preparation instructions
see <content styleCode="italics">Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>)</content>.</paragraph>
                        <paragraph ID="p335511301546456787">
                           <content styleCode="bold">Table 1: Recommended Adult Dosage and Administration of Kinevac by
Treatment Indication</content>
                        </paragraph>
                        <table ID="t28191530" border="1">
                           <colgroup>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Indication</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Recommended Adult Dosage
and Administration of KINEVAC</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">To stimulate contraction of
the gallbladder</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph ID="p36113301546456960">Kinevac 0.02 mcg/kg as a single dose over 30 to 60 seconds via intravenous
injection. If satisfactory contraction does not occur in 15 minutes,
administer a dose of 0.04 mcg/kg over 30 to 60 seconds.</paragraph>
                                    <paragraph ID="p36092301546456953">
                                       <content styleCode="underline">Alternatively, Consider
an Intravenous Infusion to Reduce Gastrointestinal Adverse Reactions </content>
                                       <content styleCode="italics">
                                          <content styleCode="underline">[see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>
                                       </content>
                                       <content styleCode="italics">: </content>0.12 mcg/kg diluted in 100 mL of 0.9% Sodium Chloride Injection USP
and infused over 50 minutes at a rate of 2 mL per minute.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">To stimulate pancreatic secretion
in combination with secretin for injection</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph ID="p25805301546457018">Secretin for Injection: 0.25 units/kg as intravenous infusion over
60 minutes</paragraph>
                                    <paragraph ID="p25630301546457022">Kinevac:
30 minutes after initiation of secretin infusion, administer Kinevac
0.02 mcg/kg diluted in 30 mL of 0.9% Sodium Chloride Injection USP
and infused over 30 minutes at a rate of 1 mL per minute.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">To accelerate the transit of
a barium meal through the small intestine</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph ID="p25754301546457026">After the barium meal is beyond the proximal jejunum, administer
Kinevac 0.04 mcg/kg over 30 to 60 seconds via intravenous injection.</paragraph>
                                    <paragraph ID="p384114301546457066">If satisfactory transit of the
barium meal has not occurred in 30 minutes, administer a second dose
of 0.04 mcg/kg over 30 to 60 seconds.</paragraph>
                                    <paragraph ID="p384513301546457070">
                                       <content styleCode="underline">Alternatively, Consider an Intravenous
Infusion to Reduce Gastrointestinal Adverse Reactions </content>
                                       <content styleCode="italics">
                                          <content styleCode="underline">[see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>
                                       </content>
                                       <content styleCode="italics">: </content>0.12 mcg/kg diluted in 100 mL 0.9% Sodium Chloride Injection USP
and infused over 30 minutes.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p15441301690664351"/>
                     </text>
                     <effectiveTime value="20230801"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="cab9ffdb-647a-47ea-ba8f-e77b3aa3e340"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Preparation
Instructions</title>
                     <text>
                        <paragraph ID="p54166301546463000">
                           <content styleCode="underline">For Intravenous Injection</content>
                        </paragraph>
                        <list listType="unordered" ID="l59193301546463026" styleCode="Disc">
                           <item>Reconstitute Kinevac aseptically by adding 5 mL of Sterile Water for Injection USP to the vial.</item>
                           <item>Inspect the reconstituted solution visually for particulate matter and discoloration after reconstitution and prior to administration.</item>
                           <item>Withdraw the prescribed dose of the reconstituted solution from the vial and administer as an intravenous injection over 30 to 60 seconds, as shown in Table 1. Discard the unused portion.</item>
                           <item>Store the reconstituted solution at room temperature. <content styleCode="italics">
                                 <content styleCode="underline">Discard after 8 hours.</content>
                              </content>
                           </item>
                           <item>For single use only; discard unused portion.</item>
                        </list>
                        <paragraph ID="p30857301546463115">
                           <content styleCode="underline">For Intravenous Infusion </content>
                        </paragraph>
                        <list listType="unordered" ID="l64231301546463126" styleCode="Disc">
                           <item>Reconstitute Kinevac aseptically by adding 5 mL of Sterile Water for Injection USP to the vial.</item>
                           <item>After reconstitution, withdraw the prescribed dose of the solution from the vial. Discard unused portion.</item>
                           <item>Dilute the reconstituted solution in 30 mL or 100 mL of 0.9% Sodium Chloride Injection USP, depending on the indication, as described in Table 1.</item>
                           <item>Inspect the Kinevac solutions visually for particulate matter and discoloration after reconstitution, dilution and prior to administration.</item>
                           <item>Store the diluted solution at room temperature. <content styleCode="italics">
                                 <content styleCode="underline">Discard after 1 hour</content>
                              </content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="ac5acacd-bda2-4d84-8653-fdd95c3cae3b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="p69135301546463211">For injection: 5 mcg of sincalide
as a lyophilized white powder for reconstitution in a single-dose
vial.</paragraph>
               </text>
               <effectiveTime value="20181201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p6932116161546533316">For injection: 5 mcg of sincalide
as a lyophilized powder in a single-dose vial for reconstitution (<linkHtml href="#Section_3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="4561b118-19af-1d0d-689e-db302fb40f32"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="p69244301546463238">
                     <content styleCode="xmChange">KINEVAC is contraindicated
in patients with:</content>
                  </paragraph>
                  <list listType="unordered" ID="l69294301546463244" styleCode="Disc">
                     <item>
                        <content styleCode="xmChange">a history of hypersensitivity to sulfites
or sincalide. Serious hypersensitivity reactions have included anaphylaxis
and anaphylactic shock <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>), Adverse Reactions (<linkHtml href="#Section_6">6</linkHtml>)]</content>.</content>
                     </item>
                     <item>
                        <content styleCode="xmChange">intestinal obstruction.</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l6949116161546533498" styleCode="Disc">
                           <item>History of hypersensitivity to sulfites or sincalide. (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.1">5.1</linkHtml>)</item>
                           <item>Intestinal obstruction. (<linkHtml href="#Section_4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="c7fe6f46-2ec6-2691-9a91-c568b3299acf"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l7203216161546533623" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Anaphylaxis, Anaphylactic Shock and Other Serious Hypersensitivity
Reactions</content>: Contains sodium metabisulfite. Serious reactions
may occur during or soon after administration. If symptoms occur,
discontinue the drug. (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Evacuation of Gallstones</content>: Stimulation
of gallbladder contraction in patients with small gallbladder stones
could lead to the evacuation of the stones from the gallbladder, resulting
in their lodging in the cystic duct or in the common bile duct. (<linkHtml href="#Section_5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Gastrointestinal Adverse Reactions with Intravenous
Injection</content>: Administration as an intravenous injection
may cause transient nausea, vomiting, abdominal pain or cramping,
dizziness or flushing. To reduce the risk of adverse reactions when
used to stimulate contraction of the gallbladder or accelerate transit
of a barium meal through the small intestine, administer as an intravenous
infusion over 50 or 30 minutes, respectively. (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Preterm Labor or Spontaneous Abortion</content>: Advise pregnant women of the potential risk for preterm labor and
spontaneous abortion. (<linkHtml href="#Section_5.4">5.4</linkHtml>, <linkHtml href="#Section_8.1">8.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="3f16b711-864b-0c56-8551-a14785c4d2fb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Anaphylaxis, Anaphylactic
Shock and Other Serious Hypersensitivity Reactions </title>
                     <text>
                        <paragraph ID="p66848301690664679">
                           <content styleCode="xmChange">Contains sodium
metabisulfite <content styleCode="italics">[see Description (<linkHtml href="#Section_11">11</linkHtml>)]</content>, a sulfite that may cause allergic-type reactions including
anaphylactic symptoms and life-threatening or less severe asthmatic
episodes in certain susceptible people. The overall prevalence of
sulfite sensitivity in the general population is unknown and probably
low. Sulfite sensitivity is seen more frequently in asthmatic than
in non-asthmatic people.</content>
                        </paragraph>
                        <paragraph ID="p69578301546463344">
									In postmarketing experience,
anaphylaxis, anaphylactic shock and other serious hypersensitivity
reactions have been reported during and within one hour following
administration of Kinevac <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6">6</linkHtml>)]</content>.
								</paragraph>
                        <paragraph ID="p71822301546463354">
                           <content styleCode="xmChange">Kinevac is
contraindicated in patients with a history of hypersensitivity to
sulfites. Due to the potential for anaphylaxis, appropriate medical
support should be readily available when Kinevac is administered.
If anaphylaxis or other hypersensitivity reactions occur, immediately
discontinue the infusion and initiate appropriate medical treatment.
Observe patients closely during and after the infusion. Do not reinitiate
Kinevac in patients who have experienced symptoms of hypersensitivity <content styleCode="italics">[see Contraindications (<linkHtml href="#Section_4">4</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230801"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="83591a2f-ae87-4c9a-8643-21a7d8622181"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Evacuation
of Gallstones</title>
                     <text>
                        <paragraph ID="p72012301546463412">Stimulation of gallbladder contraction in patients with small gallbladder stones could lead to the evacuation of the stones from the gallbladder, resulting in their lodging in the cystic duct or in the common bile duct.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="35c0479d-8a8e-444d-bad0-48542b33bad6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Gastrointestinal Adverse Reactions with Intravenous Injection</title>
                     <text>
                        <paragraph ID="p72042301546463429">Administration of Kinevac as an intravenous injection may cause adverse reactions such as nausea, vomiting, abdominal pain or cramping, dizziness, and flushing <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6">6</linkHtml>)]</content>. These reactions are generally transient. To reduce the risk of adverse reactions with intravenous injection when used to stimulate contraction of the gallbladder or accelerate transit of a barium meal through the small intestine, administer Kinevac as an intravenous infusion over 50 or 30 minutes, respectively <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221101"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="f06099bf-f3f6-452f-88bc-333e5325ab61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Preterm
Labor or Spontaneous Abortion</title>
                     <text>
                        <paragraph ID="p74291301546463479">Because of Kinevac’s effect on smooth muscle,
pregnant patients should be advised that spontaneous abortion or premature
induction of labor may occur <content styleCode="italics">[see Use in Specific Populations
(<linkHtml href="#Section_8.1">8.1</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="06f7ba2d-3f67-329d-0817-babf6b86f401"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="p8233315431697684570">The following clinically significant adverse
reactions are described elsewhere in labeling:</paragraph>
                  <list listType="unordered" ID="l8451515431697684598" styleCode="Disc">
                     <item>Anaphylaxis, anaphylactic shock, and other serious hypersensitivity
reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section-5.1">5.1</linkHtml>)]</content>
                     </item>
                     <item>Evacuation of gallstones <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>
                     </item>
                     <item>Adverse reactions with intravenous injection <content styleCode="italics">[see
Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>
                     </item>
                     <item>Preterm labor or spontaneous abortion <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>
                     </item>
                  </list>
                  <paragraph ID="p74401301546465325">The following adverse reactions
associated with the use of Kinevac were identified in clinical trials
or postmarketing reports. Because these reactions were reported voluntarily
from a population of uncertain size, it is not always possible to
estimate their frequency, reliably, or to establish a causal relationship
to drug exposure.</paragraph>
                  <paragraph ID="p74431301546465335">The
most frequent adverse reactions (20% or greater) are gastrointestinal:
abdominal discomfort or pain, and nausea; these may not necessarily
indicate an abnormality of the biliary tract unless there is other
clinical or radiologic evidence of disease.</paragraph>
                  <paragraph ID="p74461301546465343">Less common adverse reactions include:</paragraph>
                  <paragraph ID="p74491301546465349">
                     <content styleCode="italics">Hypersensitivity reactions</content>: anaphylaxis and anaphylactic shock, hypotension, throat tightness,
bradycardia, shortness of breath, nausea, abdominal cramping, diaphoresis,
hives, rash, itching; and numbness of face, lips and eyes <content styleCode="italics">[see Contraindications (<linkHtml href="#Section_4">4</linkHtml>), (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p74671301546465385">
                     <content styleCode="italics">Neurological reactions</content>: seizures,
headache.</paragraph>
                  <paragraph ID="p74682301546465393">
                     <content styleCode="italics">Vasovagal
reactions</content>: dizziness, loss of consciousness, nausea, diaphoresis,
syncope and hypotension (generally self-limiting).</paragraph>
                  <paragraph ID="p76852301546465401">
                     <content styleCode="italics">Other: </content>nausea, vomiting,
flushing, hypertension, urge to defecate, diarrhea, sneezing.</paragraph>
               </text>
               <effectiveTime value="20231018"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p7721216161546535131">Most common adverse reactions
(≥20%) are: abdominal discomfort or pain, and nausea. (<linkHtml href="#Section_6">6</linkHtml>)</paragraph>
                        <paragraph ID="p7936116161546535207">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Bracco Diagnostics Inc. at 1-800-257-5181 or FDA at 1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="6e790f99-e8ed-435a-a49f-183efe3ea885"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20221101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p7938016161546535286">
                           <content styleCode="underline">Drugs that Affect
Gallbladder Motility or Contractile Response</content>:  May interfere
with response to sincalide.  Consider discontinuing these drugs prior
to administration of Kinevac, when used to stimulate contraction of
the gallbladder. (<linkHtml href="#Section_7.1">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="c08ecd6e-917d-4184-90e3-210e58a51294"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs
that Affect Gallbladder Motility or Contractile Response</title>
                     <text>
                        <paragraph ID="p76863301546465425">Drugs that may stimulate or inhibit gallbladder motility or contractile response may interfere with the response to sincalide. Consider discontinuing these drugs prior to administration of Kinevac, when used to stimulate contraction of the gallbladder.</paragraph>
                     </text>
                     <effectiveTime value="20221101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="333db767-ccea-4790-a9ce-800ed25f1b2c"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20181201"/>
               <component>
                  <section ID="Section_8.1">
                     <id root="d04c3ac3-8688-4e6d-8197-4681d738fdbe"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="p76923301546465435">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph ID="p76992301546465447">Based on limited human data and mechanism
of action, sincalide may cause preterm labor or spontaneous abortion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)].</content> Available data with sincalide for injection are insufficient
to establish a drug-associated risk of major birth defects, miscarriage
or adverse maternal or fetal outcomes. In animal embryo-fetal development
studies in which sincalide was administered to hamsters and rats during
the period of organogenesis, no effects were seen at doses comparable
to the maximum recommended clinical dose on a mg/kg basis. However,
in a prenatal development study in which rats were administered sincalide
during organogenesis through parturition, decreased weight gain and
developmental delays were observed at a dose 122 times higher than
the maximum recommended human dose based on body surface area.</paragraph>
                        <paragraph ID="p77122301546465479">The estimated background risk
of major birth defects and miscarriage for the indicated population
is unknown. All pregnancies have a background risk of birth defect,
loss, or other adverse outcomes. In the U.S. general population, the
estimated background risk of major birth defects and miscarriage in
clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. </paragraph>
                        <paragraph ID="p77133301546465489">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph ID="p79397301546465503">
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph ID="p79443301546465517">There were no effects on embryo-fetal
development in hamsters when sincalide was administered subcutaneously
at 250 or 750 ng/kg during organogenesis (Gestation Days 7 to 13)
at doses up to 0.8 times the maximum recommended dose of 120 ng/kg
on a body surface area basis. No effects on embryo-fetal development
were observed in Sprague-Dawley rats at subcutaneous doses of 250,
450, or 750 ng/kg from Gestation Days 6 to16, representing 1.0 time
the maximum recommended human dose on a body surface area basis. In
a separate study at a higher dose of 90 mcg/kg administered subcutaneously
to CFY rats from Gestation Day 10 through parturition (representing
122 times the maximum recommended human dose on a body surface area
basis), offspring showed decreased growth, behavioral changes, and
developmental delays.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
               <component>
                  <section ID="s2081116161546527847">
                     <id root="a9a38f13-a07f-43ff-81c0-055c5825acb0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="f2520b78-29e8-42b2-9bbc-0e60b62323a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="p79468301546465536">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph ID="p79523301546465539">There are no data regarding the presence of
sincalide in human or animal milk, the effects on the breastfed infant,
or the effects on milk production. The developmental and health benefits
of breastfeeding should be considered along with the mother’s clinical
need for Kinevac and any potential adverse effect on the breastfed
infant from Kinevac or from the underlying condition.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="2e772992-64e1-485b-a2e2-20c0c3381e91"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric
Use</title>
                     <text>
                        <paragraph ID="p79534301546465557">The safety
and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="b5cf8ab9-b3c8-47ca-9070-5aeeac4a4a7a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric
Use</title>
                     <text>
                        <paragraph ID="p79596301546465575">Clinical
studies of Kinevac did not include sufficient numbers of subjects
aged 65 and over to determine whether they respond differently from
younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="b0ccffba-b542-4a13-a77e-ea9ece1d0a7e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="p79607301546465588">In the event of an overdose, symptoms related to vagal stimulation,
such as gastrointestinal symptoms (abdominal cramps, nausea, vomiting
and diarrhea), hypotension with dizziness or fainting may occur. Overdosage
symptoms should be treated symptomatically and should be of short
duration.</paragraph>
                  <paragraph ID="p79624301546465597">A single bolus
intravenous injection of 0.05 mcg/kg (approximately 2 to 3 times the
human dose of 0.02 mcg/kg), sincalide caused hypotension and bradycardia
in dogs. In addition, higher doses injected intravenously once or
repeatedly in dogs caused syncope and ECG changes (approximately 5
times the human dose of 0.02 mcg/kg). These effects were attributed
to sincalide-induced vagal stimulation in that all were prevented
by pretreatment with atropine or bilateral vagotomy.</paragraph>
               </text>
               <effectiveTime value="20181201"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="0c903d7e-120c-40c8-893f-0781b930d58e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="p79654301546465615">Kinevac (sincalide for injection)
is a cholecystopancreatic-gastrointestinal hormone for parenteral
administration. The agent is a synthetically-prepared C-terminal octapeptide
of cholecystokinin.</paragraph>
                  <paragraph ID="p79684301546465633">Each single-dose vial of sincalide provides a sterile nonpyrogenic
lyophilized white powder consisting of 5 mcg sincalide with 30 mg
arginine hydrochloride, 15 mg lysine hydrochloride, 170 mg mannitol,
4 mg methionine, 2 mg pentetic acid, 0.005 mcg polysorbate 20, 9 mg
potassium phosphate dibasic, and 0.04 mg sodium metabisulfite.</paragraph>
                  <paragraph ID="p79714301546465641">The pH is adjusted to 6.0 to 8.0
with hydrochloric acid and/or sodium hydroxide prior to lyophilization.
Sincalide is designated chemically as L-α-aspartyl-O-sulfo-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-
L-α-aspartyl-L-phenylalaninamide. Graphic formula:</paragraph>
                  <renderMultiMedia referencedObject="g20836221363704588"/>
               </text>
               <effectiveTime value="20181201"/>
               <component>
                  <observationMedia ID="g20836221363704588">
                     <text>kinevac-struct</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kinevac-struct.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="a66ff7d5-5290-419c-a145-656f998abac6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20181201"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="9141a865-c42f-4501-9690-df19099bcbcd"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="p54149301546465700">When injected intravenously, sincalide stimulates
gallbladder contraction and reduction in size. The evacuation of bile
that results is similar to that which occurs physiologically in response
to endogenous cholecystokinin. Sincalide also stimulates pancreatic
secretion and intestinal motility causing pyloric contraction and
slows gastric emptying.</paragraph>
                        <paragraph ID="p79786301546465706">Concurrent administration of sincalide with secretin increases both
the volume of pancreatic secretion and the out-put of bicarbonate
and enzymes. This combined effect of secretin and sincalide permits
the assessment of specific pancreatic function through measurement
and analysis of the duodenal aspirate.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="58b0cc6e-5f85-4ec0-97f9-487aa92ed514"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="p79804301546465718">Following an intravenous (bolus) injection
of 0.02 mcg/kg of sincalide, maximal contraction of the gallbladder
occurred in 5 to 15 minutes. Sincalide reduced gallbladder radiographic
size by at least 40%, which is generally considered satisfactory contraction.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="1698b53c-f044-46d2-9829-537168af715c"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20181201"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="32d91e81-df73-4104-b9a3-375619059c74"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="p79834301546465732">Long-term studies in animals have
not been performed to evaluate carcinogenic or mutagenic potential,
or possible impairment of fertility in males or females.</paragraph>
                     </text>
                     <effectiveTime value="20181201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="59764a48-b543-4921-b581-66727252f4f4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph ID="p81942301546465741">Kinevac (sincalide for injection) is supplied
as 5 mcg of sincalide as a lyophilized white powder for reconstitution
in a single-dose vial; in packages of 10 vials (NDC 0270-0556-15).</paragraph>
                  <paragraph ID="p81962301546465772">Store at 25° C (77° F); excursions
permitted to 15-30° C (59-86° F) [See USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20181201"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="7f2543e9-f419-9a5c-45af-5a2f83d90629"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="p82007301546465785">
                     <content styleCode="underline">Anaphylaxis, Anaphylactic Shock
and Other Serious Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph ID="p82052301546465802">Inform patients that serious hypersensitivity
reactions, including anaphylaxis and anaphylactic shock have been
reported during or following administration of Kinevac. Advise patients
to report immediately to a healthcare provider if they experience
symptoms of a hypersensitivity reaction <content styleCode="italics">[see Warnings and
Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph ID="p82162301546465838">
                     <content styleCode="underline">Gastrointestinal
Adverse Reactions</content>
                  </paragraph>
                  <paragraph ID="p82173301546465841">Advise patients that Kinevac may cause transient
gastrointestinal symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p82322301546465877">
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph ID="p82372301546465886">Advise pregnant women of the potential
risk for preterm labor and spontaneous abortion <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>), Use in Specific
Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph ID="p315301546465984">U.S. Patent 6,803,046</paragraph>
                  <paragraph ID="p214301546465991">
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph ID="p143301546465999">Manufactured for<br/>Bracco
Diagnostics Inc.<br/>Monroe Township, NJ 08831<br/>By
Fresenius Kabi USA, LLC<br/>Lake Zurich, Illinois 60047</paragraph>
               </text>
               <effectiveTime value="20230801"/>
            </section>
         </component>
         <component>
            <section ID="g22f86a87-ece2-8f9d-aba2-3244982de25c">
               <id root="e9011a83-872f-a1dd-5e32-7e0c1090d13d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p1232213432263703154">Kinevac
5 mcg Vial Label<br/>NDC: 0270-0556-15</paragraph>
                  <renderMultiMedia referencedObject="g15516001697685371"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="g15516001697685371">
                     <text>kinevac vial label-fk-403895</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kinevac vial label-fk-403895.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="g29e5794d-1122-beae-7d70-557c8e90ff95">
               <id root="75d439d6-5741-8aaf-480b-79590deda0b9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p123221363323703490">Kinevac
5 mcg Carton Label<br/>NDC: 0270-0556-15</paragraph>
                  <renderMultiMedia referencedObject="g15516051697685476"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="g15516051697685476">
                     <text>kinevac carton label-fk-421034</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kinevac carton label-fk-421034.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>